These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35892377)

  • 1. Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections-Overview of Policies Applied in 17 European Countries.
    Vogler S; Windisch F
    Antibiotics (Basel); 2022 Jul; 11(8):. PubMed ID: 35892377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers and Facilitators in Pricing and Funding Policies of European Countries That Impact the Use of Point-of-Care Diagnostics for Acute Respiratory Tract Infections in Outpatient Practices.
    Steigenberger C; Windisch F; Vogler S
    Diagnostics (Basel); 2023 Dec; 13(23):. PubMed ID: 38066837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally.
    Vogler S; Habimana K; Haasis MA; Fischer S
    Appl Health Econ Health Policy; 2024 Sep; 22(5):629-652. PubMed ID: 38837100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab.
    Leopold C; Vogler S; Habl C; Mantel-Teeuwisse AK; Espin J
    Health Policy; 2013 Dec; 113(3):313-22. PubMed ID: 24409503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stakeholders' views and experiences on implementing new diagnostics in primary care to support management of community-acquired acute respiratory tract infections: a qualitative study.
    Hoste ME; Colman E; Wanat M; Hayward G; Tissier JL; Postma M; Goossens H; Anthierens S; Tonkin-Crine S;
    Front Public Health; 2023; 11():1216940. PubMed ID: 37583883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?
    Vogler S; Salcher-Konrad M; Habimana K
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):867-878. PubMed ID: 37450611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic Medicine Pricing Policies in Europe: Current Status and Impact.
    Dylst P; Simoens S
    Pharmaceuticals (Basel); 2010 Mar; 3(3):471-481. PubMed ID: 27713264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of external reference pricing systems in Europe.
    Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.
    Kawalec P; Tesar T; Vostalova L; Draganic P; Manova M; Savova A; Petrova G; Rugaja Z; Männik A; Sowada C; Stawowczyk E; Harsanyi A; Inotai A; Turcu-Stiolica A; Gulbinovič J; Pilc A
    Front Pharmacol; 2017; 8():892. PubMed ID: 29326583
    [No Abstract]   [Full Text] [Related]  

  • 11. The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance.
    van der Pol S; Jansen DEMC; van der Velden AW; Butler CC; Verheij TJM; Friedrich AW; Postma MJ; van Asselt ADI
    Pharmacoeconomics; 2022 Aug; 40(8):823-833. PubMed ID: 35764913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
    Vogler S; Schneider P; Zuba M; Busse R; Panteli D
    Front Pharmacol; 2021; 12():625296. PubMed ID: 34248615
    [No Abstract]   [Full Text] [Related]  

  • 14. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
    Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
    Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policies and availability of orphan medicines in outpatient care in 24 European countries.
    Sarnola K; Ahonen R; Martikainen JE; Timonen J
    Eur J Clin Pharmacol; 2018 Jul; 74(7):895-902. PubMed ID: 29632962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe.
    Henshall CH; Dankó D; Barham L; Espín J; Felix J; Harney M; Indra P; Mestre-Ferrandiz J; de Pouvourville G; Spandonaro F; Vončina L; Wilking N
    Appl Health Econ Health Policy; 2023 Jul; 21(4):537-546. PubMed ID: 36897550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis.
    Dahmani H; Fradi I; Achour L; Toumi M;
    J Mark Access Health Policy; 2023; 11(1):2244304. PubMed ID: 37614557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal trends of and factors associated with inappropriate antibiotic prescribing for non-bacterial acute respiratory tract infection in Japan: A retrospective claims database study, 2012-2017.
    Kimura Y; Fukuda H; Hayakawa K; Ide S; Ota M; Saito S; Ishikane M; Kusama Y; Matsunaga N; Ohmagari N
    PLoS One; 2019; 14(10):e0223835. PubMed ID: 31618258
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.